Home / IRIX : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does IRIX make money? Does IRIX have pricing power? What's the Earnings Whisper? Will IRIX profit more as the business scales? What is IRIX's management track record? Is IRIX's current price justified?

IRIDEX Corporation

$0.64 -$0.53 (-45.30%)

NASDAQ · 14 Sep 2026 20:00 UTC

Previous Close

$0.66

Day Range

$0.62$0.66

Year Range

$0.62$1.65

Market Cap

11.08M

AVG Volume

67.58K

Trailing/Forward PE

-3.15/32

PEG ratio

0.03

Dividend Yield

Next Earnings Date

2026-11-17

Primary Exchange

NASDAQ

Revenue (USD)

IRIX Revenue (USD) by quarter
Period	Revenue (USD)
26 Q2	12.57M
26 Q1	11.8M
25 Q4	14.72M
25 Q3	12.48M
25 Q2	13.57M
25 Q1	11.9M
24 Q4	12.7M
24 Q3	11.58M
24 Q2	12.63M
24 Q1	11.76M

Net Income (USD)

IRIX Net Income (USD) by quarter
Period	Net Income (USD)
26 Q2	-1.27M
26 Q1	-524K
25 Q4	-184K
25 Q3	-1.57M
25 Q2	-994K
25 Q1	-1.69M
24 Q4	-834K
24 Q3	-1.93M
24 Q2	-2.68M
24 Q1	-3.46M

Operating Income (USD)

IRIX Operating Income (USD) by quarter
Period	Operating Income (USD)
26 Q2	-1.03M
26 Q1	-324K
25 Q4	-15K
25 Q3	-1.41M
25 Q2	-940K
25 Q1	-205K
24 Q4	-502K
24 Q3	-1.87M
24 Q2	-2.64M
24 Q1	-3.29M

EBITDA (USD)

IRIX EBITDA (USD) by quarter
Period	EBITDA (USD)
26 Q2	-667K
26 Q1	-94K
25 Q4	258K
25 Q3	-1.2M
25 Q2	-595K
25 Q1	-1.29M
24 Q4	-463K
24 Q3	-1.64M
24 Q2	-2.29M
24 Q1	-3.02M

Cash Flows (USD)

IRIX Cash Flows (USD) by quarter
Period	Cash Flows (USD)
26 Q2	275K
26 Q1	-1.44M
25 Q4	565K
25 Q3	-1.17M
25 Q2	-410K
25 Q1	-1.16M
24 Q4	-1.25M
24 Q3	-3.07M
24 Q2	-1.33M
24 Q1	-1.65M

EPS (USD)

IRIX EPS (USD) by quarter
Period	EPS (USD)
26 Q2	-0.07
26 Q1	-0.03
25 Q4	-0.01
25 Q3	-0.09
25 Q2	-0.06
25 Q1	-0.1
24 Q4	-0.05
24 Q3	-0.12
24 Q2	-0.16
24 Q1	-0.21

Expenses (USD)

IRIX Expenses (USD) by quarter
Period	Expenses (USD)
26 Q2	5.22M
26 Q1	5.17M
25 Q4	5.52M
25 Q3	5.44M
25 Q2	5.63M
25 Q1	5.27M
24 Q4	6.1M
24 Q3	6.19M
24 Q2	7.77M
24 Q1	7.75M

Cash & Debt (USD)

IRIX Cash & Debt (USD) by quarter
Period	Cash & Debt (USD)
26 Q2	4.68M
26 Q1	4.59M
25 Q4	6.03M
25 Q3	5.57M
25 Q2	6.78M
25 Q1	7.24M
24 Q4	2.39M
24 Q3	3.86M
24 Q2	4.11M
24 Q1	5.42M

Debt ratios

IRIX Debt ratios by quarter
Period	Debt ratios
26 Q2	0.39
26 Q1	0.2
25 Q4	0.53
25 Q3	0.22
25 Q2	0.43
25 Q1	0.34
24 Q4	-0.3
24 Q3	-0.12
24 Q2	0.21
24 Q1	0.33

Margins

IRIX Margins by quarter
Period	Margins
26 Q2	34.19%
26 Q1	40.18%
25 Q4	38.27%
25 Q3	32.15%
25 Q2	33.92%
25 Q1	42.49%
24 Q4	44%
24 Q3	37.33%
24 Q2	40.65%
24 Q1	37.19%

Return on Capital

IRIX Return on Capital by quarter
Period	Return on Capital
26 Q2	-34.79%
26 Q1	-11.07%
25 Q4	-3.74%
25 Q3	-33.6%
25 Q2	-16.41%
25 Q1	-197.89%
24 Q4	-39.77%
24 Q3	-73.69%
24 Q2	-63.09%
24 Q1	-53.39%

Shares Outstanding

IRIX Shares Outstanding by quarter
Period	Shares Outstanding
26 Q2	17.38M
26 Q1	17.31M
25 Q4	17.19M
25 Q3	17.01M
25 Q2	16.79M
25 Q1	16.73M
24 Q4	16.64M
24 Q3	16.58M
24 Q2	16.29M
24 Q1	16.25M

Book Value Per Share (USD)

IRIX Book Value Per Share (USD) by quarter
Period	Book Value Per Share (USD)
26 Q2	0.21
26 Q1	0.27
25 Q4	0.29
25 Q3	0.28
25 Q2	0.36
25 Q1	0.05
24 Q4	0.13
24 Q3	0.16
24 Q2	0.26
24 Q1	0.4

Total Assets (USD)

IRIX Total Assets (USD) by quarter
Period	Total Assets (USD)
26 Q2	27.26M
26 Q1	28.27M
25 Q4	29.15M
25 Q3	28.35M
25 Q2	31.59M
25 Q1	34.24M
24 Q4	29.14M
24 Q3	30.15M
24 Q2	31.25M
24 Q1	34.09M

Employee Count

IRIX Employee Count by quarter
Period	Employee Count
2026	93
2024	93
2023	111
2022	130
2022	119
2021	89
2019	11
2018	17
2017	38
2016	121

Free Cash Flow Yield

IRIX Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-15.89%
Sep 26	-15.41%
Sep 26	-14.53%
Aug 26	-14.39%
Aug 26	-13.45%
Aug 26	-16.55%
Aug 26	-17.06%
Jul 26	-17.27%
Jul 26	-15.9%
Jul 26	-15.16%
Jul 26	-12.88%
Jul 26	-12.53%
Jun 26	-12.53%
Jun 26	-12.53%
Jun 26	-12.65%
Jun 26	-12.99%
May 26	-13.49%
May 26	-14.02%
May 26	-12.54%
May 26	-12.29%
May 26	-12.29%
Apr 26	-11.94%
Apr 26	-11.94%
Apr 26	-12.66%
Apr 26	-12.92%
Mar 26	-23.68%
Mar 26	-17.37%
Mar 26	-18.04%
Mar 26	-18.91%
Feb 26	-16.75%
Feb 26	-16.87%
Feb 26	-16.99%
Feb 26	-16.06%
Jan 26	-15.74%
Jan 26	-15.43%
Jan 26	-16.63%
Jan 26	-20.39%
Jan 26	-20.04%
Dec 25	-19.06%
Dec 25	-23.45%
Dec 25	-25.46%
Dec 25	-24.94%
Nov 25	-24.42%
Nov 25	-25.21%
Nov 25	-23.92%
Nov 25	-33.09%
Oct 25	-33.41%
Oct 25	-31.89%
Oct 25	-33.73%
Oct 25	-33.73%
Oct 25	-29.23%
Sep 25	-30.5%
Sep 25	-29.48%
Sep 25	-26.58%
Sep 25	-25.06%
Aug 25	-26.18%
Aug 25	-28.29%
Aug 25	-31.04%
Aug 25	-31.3%
Aug 25	-31.79%
Jul 25	-28.86%
Jul 25	-32.3%
Jul 25	-40.29%
Jul 25	-43.76%
Jun 25	-46.24%
Jun 25	-43.62%
Jun 25	-43.29%
Jun 25	-41.82%
May 25	-40.78%
May 25	-41.53%
May 25	-40.29%
May 25	-38.15%
May 25	-36.86%
Apr 25	-35.96%
Apr 25	-43.01%
Apr 25	-46.55%
Apr 25	-50.9%
Mar 25	-43.91%
Mar 25	-42.63%
Mar 25	-37.35%
Mar 25	-33.5%
Feb 25	-30.58%
Feb 25	-27.95%
Feb 25	-27.23%
Feb 25	-26.21%
Jan 25	-25.73%
Jan 25	-25.73%
Jan 25	-25.42%
Jan 25	-25.58%
Jan 25	-23.84%
Dec 24	-25.27%
Dec 24	-25.73%
Dec 24	-24.54%
Dec 24	-23.58%
Nov 24	-23.58%
Nov 24	-23.45%
Nov 24	-24.97%
Nov 24	-25.57%
Nov 24	-23.69%
Oct 24	-23.38%

Price to Sales

IRIX Price to Sales by quarter
Period	Price to Sales
Sep 26	0.22
Sep 26	0.22
Sep 26	0.24
Aug 26	0.24
Aug 26	0.25
Aug 26	0.28
Aug 26	0.27
Jul 26	0.27
Jul 26	0.29
Jul 26	0.31
Jul 26	0.36
Jul 26	0.37
Jun 26	0.37
Jun 26	0.37
Jun 26	0.37
Jun 26	0.36
May 26	0.35
May 26	0.33
May 26	0.33
May 26	0.34
May 26	0.34
Apr 26	0.35
Apr 26	0.35
Apr 26	0.33
Apr 26	0.32
Mar 26	0.33
Mar 26	0.45
Mar 26	0.44
Mar 26	0.42
Feb 26	0.47
Feb 26	0.47
Feb 26	0.46
Feb 26	0.49
Jan 26	0.5
Jan 26	0.51
Jan 26	0.47
Jan 26	0.39
Jan 26	0.39
Dec 25	0.41
Dec 25	0.34
Dec 25	0.31
Dec 25	0.32
Nov 25	0.32
Nov 25	0.31
Nov 25	0.33
Nov 25	0.36
Oct 25	0.35
Oct 25	0.37
Oct 25	0.35
Oct 25	0.35
Oct 25	0.41
Sep 25	0.39
Sep 25	0.4
Sep 25	0.45
Sep 25	0.47
Aug 25	0.45
Aug 25	0.42
Aug 25	0.38
Aug 25	0.45
Aug 25	0.44
Jul 25	0.48
Jul 25	0.43
Jul 25	0.35
Jul 25	0.32
Jun 25	0.3
Jun 25	0.32
Jun 25	0.32
Jun 25	0.33
May 25	0.34
May 25	0.34
May 25	0.35
May 25	0.39
May 25	0.41
Apr 25	0.42
Apr 25	0.35
Apr 25	0.32
Apr 25	0.29
Mar 25	0.34
Mar 25	0.34
Mar 25	0.39
Mar 25	0.43
Feb 25	0.47
Feb 25	0.52
Feb 25	0.53
Feb 25	0.55
Jan 25	0.56
Jan 25	0.56
Jan 25	0.57
Jan 25	0.56
Jan 25	0.61
Dec 24	0.57
Dec 24	0.56
Dec 24	0.59
Dec 24	0.61
Nov 24	0.61
Nov 24	0.62
Nov 24	0.58
Nov 24	0.46
Nov 24	0.49
Oct 24	0.5

Price/Operating Cashflow

IRIX Price/Operating Cashflow by quarter
Period	Price/Operating Cashflow
May 22	6.54
Apr 22	7.24
Apr 22	7.7
Apr 22	8.21
Apr 22	8.19
Apr 22	8.81
Mar 22	8.36
Mar 22	8.74
Mar 22	6.5
Mar 22	6.9
Feb 22	7.01
Feb 22	7.36
Feb 22	7.76
Feb 22	8.12
Jan 22	8.09
Jan 22	8.03
Jan 22	8.85
Jan 22	9.15
Dec 21	9.69
Dec 21	9.87
Dec 21	9.2
Dec 21	10
Dec 21	9.44
Nov 21	10.34
Nov 21	12.12
Nov 21	12.76
Nov 21	13.57
Oct 21	11.11
Oct 21	10.94
Oct 21	10.73
Oct 21	11.49
Oct 21	10.88
Sep 21	10.85
Sep 21	10.44
Sep 21	10.52
Sep 21	10.29
Aug 21	10.94
Aug 21	11.01
Aug 21	11.56
Aug 21	9.4
Jul 21	9.34
Jul 21	9.41
Jul 21	8.98
Jul 21	9.45
Jul 21	10.17
Jun 21	10.57
Jun 21	10
Jun 21	11.05
Jun 21	10.85
May 21	11.22
May 21	11
May 21	10.7

Price to Book

IRIX Price to Book by quarter
Period	Price to Book
Sep 26	3.06
Sep 26	3.15
Sep 26	3.34
Aug 26	3.37
Aug 26	3.61
Aug 26	3.13
Aug 26	3.04
Jul 26	3
Jul 26	3.26
Jul 26	3.42
Jul 26	4.02
Jul 26	4.13
Jun 26	4.13
Jun 26	4.13
Jun 26	4.1
Jun 26	3.99
May 26	3.84
May 26	3.69
May 26	3.53
May 26	3.6
May 26	3.6
Apr 26	3.7
Apr 26	3.7
Apr 26	3.49
Apr 26	3.42
Mar 26	3.6
Mar 26	4.91
Mar 26	4.72
Mar 26	4.51
Feb 26	5.09
Feb 26	5.05
Feb 26	5.01
Feb 26	5.31
Jan 26	5.41
Jan 26	5.52
Jan 26	5.12
Jan 26	4.18
Jan 26	4.25
Dec 25	4.47
Dec 25	3.63
Dec 25	3.35
Dec 25	3.42
Nov 25	3.49
Nov 25	3.38
Nov 25	3.56
Nov 25	2.94
Oct 25	2.91
Oct 25	3.05
Oct 25	2.88
Oct 25	2.88
Oct 25	3.33
Sep 25	3.19
Sep 25	3.3
Sep 25	3.66
Sep 25	3.88
Aug 25	3.71
Aug 25	3.44
Aug 25	3.13
Aug 25	25.52
Aug 25	25.13
Jul 25	27.68
Jul 25	24.74
Jul 25	19.83
Jul 25	18.26
Jun 25	17.28
Jun 25	18.32
Jun 25	18.46
Jun 25	19.11
May 25	19.59
May 25	19.24
May 25	19.83
May 25	9.12
May 25	9.44
Apr 25	9.68
Apr 25	8.09
Apr 25	7.48
Apr 25	6.84
Mar 25	7.93
Mar 25	6.26
Mar 25	7.14
Mar 25	7.96
Feb 25	8.72
Feb 25	9.55
Feb 25	9.8
Feb 25	10.18
Jan 25	10.37
Jan 25	10.37
Jan 25	10.49
Jan 25	10.43
Jan 25	11.19
Dec 24	10.56
Dec 24	10.37
Dec 24	10.87
Dec 24	11.32
Nov 24	11.32
Nov 24	11.38
Nov 24	10.68
Nov 24	5.33
Nov 24	5.75
Oct 24	5.83

No video analysis for this stock yet. Request one from our team.

News: IRIX

zacks.com · 25 Aug 2026

IRIDEX Q2 Loss Widens Y/Y as Retina Weakness Weighs, Stock Down 15%

IRIX's Q2 loss per share widens year over year and revenues decline as Middle East disruptions and reduced sell-through in China weigh on retina sales, offsetting continued growth in the Cyclo G6 product family.

seekingalpha.com · 18 Aug 2026

IRIDEX Corporation (IRIX) Q2 2026 Earnings Call Transcript

globenewswire.com · 18 Aug 2026

Iridex Reports Second Quarter 2026 Financial Results

MOUNTAIN VIEW, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended July 4, 2026.

globenewswire.com · 4 Aug 2026

Iridex to Report Second Quarter 2026 Financial Results on August 18, 2026

MOUNTAIN VIEW, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the second quarter 2026 and provide a business update after the close of trading on August 18, 2026.

globenewswire.com · 20 Jul 2026

Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering

MOUNTAIN VIEW, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced the expansion of its EyeProGPO product offering to include the Company's line of EndoProbe® Handpieces.